Research FOR Patients
-For an informed and empowered opinion-

All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

MONOCLE IS NOW CLOSED TO RECRUITMENT

The trial was unable to demonstrate that Tefinostat had any effect in modifying CMML

    1. SUBTYPE OF MDS: Chronic myelomonocytc leukaemia (CMML)
    2. SEVERITY OF MDS: CMML specific prognostic score (CPSS) Intermediate-2 or high risk
    3. NAME OF DRUG: Tefinostat, a histone deacetylase inhibitor that targets monocytes. Tefinostat will be administered orally on a continuous basis for at least 6 cycles each 28 days in length.

  1. Aims and benefits: This is a phase 2 study aimed at determining the effectiveness of Tefinostat in CMML as well as monitoring for side effects. The study is open to patients with CMML-2 and those with CMML-1 who are symptomatic.
    Primary outcomes:

    • To determine the safety and tolerability of Tefinostat.
    • Overall clinical response rate.

    Secondary outcomes:

    • Incidence and duration of response
    • Achievement of red cell and platelet transfusion independence
    • Overall survival
    • Incidence of and time to transformation of CMML to AML
    • Quality of life
  2. Basic inclusion criteria:
    • All patients with CMML-2.
    • Patients with CMML-1 who are symptomatic (includes red cell transfusion dependent, thrombocytopenia with platelets < 50x109/L, bleeding, white cell counts > 50x109/L, weight loss, symptomatic splenomegaly, extramedullary involvement) and/or CPSS Intermediate-2 or high risk.
    • Age > 18 years
    • ECOG performance status 0-2
  3. Basic exclusion criteria:
    • CMML with raised eosinophils.
    • Patients considered suitable for allogeneic stem cell transplant.
    • Previous chemotherapy for CMML except hydroxycarbamide or 5-Azacitidine.
    • Use of experimental drugs or therapy within 28 days of registration.
    • Severe kidney or liver impairment.
    • Seropositive for HIV infection, hepatitis B or C
    • Other malignancy within 3 years other than curatively-treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated non-metastatic prostate cancer with negative prostate specific antigen, in situ breast carcinoma after complete surgical resection or superficial transitional cell bladder carcinoma.
  4. Trial sites/locations and name of physician in charge of trial: 
    University hospital of Wales, Cardiff;
    Aberdeen Royal Infirmary, Aberdeen;
    St. James’s University Hospital, Leeds.
  5. More information:

Please read information and always discuss trial information with your own physician.

Learn more about clinical trials

Check current MDS clinical trials open to recruitment

Free donations by shopping